Latest Breaking News On - Moccia al - Page 1 : comparemela.com

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.

Peter borchmannMoccia alLymphoma programDepartment of hematologyGerman hodgkin study groupUniversity hospital of cologneBristol myers squibbInternational conference on malignant lymphomaSeagen incInternational conferenceMalignant lymphomaUniversity hospitalTakeda oncologyMiltenyi biotech